miR‑130a‑3p promotes cell proliferation and invasion by targeting estrogen receptor α and androgen receptor in cervical cancer

Fan,Qiong; Huang,Ting; Sun,Xiao; Yang,Xiaoming; Wang,Jing; Liu,Yao; Ni,Ting; Gu,Shenglan; Li,Yuhong; Wang,Yudong

doi:10.3892/etm.2021.9858

miR‑130a‑3p promotes cell proliferation and invasion by targeting estrogen receptor α and androgen receptor in cervical cancer

Authors:
- Qiong Fan
- Ting Huang
- Xiao Sun
- Xiaoming Yang
- Jing Wang
- Yao Liu
- Ting Ni
- Shenglan Gu
- Yuhong Li
- Yudong Wang
View Affiliations

Affiliations: Department of Gynecological Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, P.R. China
Published online on: February 25, 2021 https://doi.org/10.3892/etm.2021.9858
Article Number: 414
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is the most common gynecological cancer in women worldwide. Human papillomavirus (HPV) is required but not sufficient for developing cervical cancer. HPV E6 and E7 proteins are able to directly interact with certain nuclear receptors; however, whether steroid hormone receptors mediate cervical carcinogenesis is not completely understood. The present study demonstrated via immunohistochemistry that estrogen receptor α (ERα) and androgen receptor (AR) expression were decreased in a sequential manner from healthy cervical tissues to cervical intraepithelial neoplasia tissues and further to cervical cancer (CC) tissues, whereas microRNA (miR)‑130a‑3p expression levels were higher in CC tissues compared with healthy tissues. Both ERα and AR were direct targets of miR‑130a‑3p, as determined by performing luciferase reporter assays and western blotting. Functionally, compared with the corresponding control groups, miR‑130a‑3p knockdown, ERα overexpression and AR overexpression significantly inhibited CC cell proliferation and invasion, as demonstrated by the results obtained from the Cell Counting Kit‑8 and Transwell assays in vitro. In addition, antagomiR‑130a decreased tumor size and weight in vivo compared with control antagomiR as determined via the xenograft tumor growth assay. Therefore, the results suggested that miR‑130a‑3p might contribute to tumor progression by suppressing ERα and AR, and serve as a promising candidate target for the treatment of patients with CC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Zhao F and Qiao Y: Cervical cancer prevention in China: A key to cancer control. Lancet. 393:969–970. 2019.PubMed/NCBI View Article : Google Scholar
3	Brasseur K, Gevry N and Asselin E: Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 8:4008–4042. 2017.PubMed/NCBI View Article : Google Scholar
4	Wu MH, Huang CJ, Liu ST, Liu PY, Ho CL and Huang SM: Physical and functional interactions of human papillomavirus E2 protein with nuclear receptor coactivators. Biochem Biophys Res Commun. 356:523–528. 2007.PubMed/NCBI View Article : Google Scholar
5	Remoue F, Jacobs N, Miot V, Boniver J and Delvenne P: High intraepithelial expression of estrogen and progesterone receptors in the transformation zone of the uterine cervix. Am J Obstet Gynecol. 189:1660–1665. 2003.PubMed/NCBI View Article : Google Scholar
6	Liang J and Shang Y: Estrogen and cancer. Annual Rev Physiol. 75:225–240. 2013.PubMed/NCBI View Article : Google Scholar
7	Rosenfeld MG and Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 276:36865–36868. 2001.PubMed/NCBI View Article : Google Scholar
8	Yang XM, Wu ZM, Huang H, Chu XY, Lou J, Xu LX, Chen YT, Wang LQ and Huang OP: Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients. Oncol Lett. 18:2771–2776. 2019.PubMed/NCBI View Article : Google Scholar
9	Sood S, Patel FD, Ghosh S, Arora A, Dhaliwal LK and Srinivasan R: Epigenetic alteration by DNA methylation of ESR1, MYOD1 and hTERT Gene promoters is useful for prediction of response in patients of locally advanced invasive cervical carcinoma treated by chemoradiation. Clin Oncol (R Coll Radiol). 27:720–727. 2015.PubMed/NCBI View Article : Google Scholar
10	Noël JC, Bucella D, Fayt I, Simonart T, Buxant F, Anaf V and Simon P: Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Int J Gynecol Pathol. 27:437–441. 2008.PubMed/NCBI View Article : Google Scholar
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
12	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005.PubMed/NCBI View Article : Google Scholar
13	Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY, Zhang HJ, Wang LH and Wan XP: A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 12(155)2013.PubMed/NCBI View Article : Google Scholar
14	Lv T, Song K, Zhang L, Li W, Chen Y, Diao Y, Yao Q and Liu P: miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol. 96:663–671. 2018.PubMed/NCBI View Article : Google Scholar
15	He L, Wang HY, Zhang L, Huang L, Li JD, Xiong Y, Zhang MY, Jia WH, Yun JP, Luo RZ and Zheng M: Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. Cell Death Dis. 5(e1205)2014.PubMed/NCBI View Article : Google Scholar
16	Bao W, Zhang Y, Li S, Fan Q, Qiu M, Wang Y, Li Y, Ji X, Yang Y, Sang Z, et al: miR1075p promotes tumor proliferation and invasion by targeting estrogen receptoralpha in endometrial carcinoma. Oncol Rep. 41:1575–1585. 2019.PubMed/NCBI View Article : Google Scholar
17	Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI and Hershman DL: Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines. Obstet Gynecol. 134:49–57. 2019.PubMed/NCBI View Article : Google Scholar
18	Fan Q, Qiu MT, Zhu Z, Zhou JH, Chen L, Zhou Y, Gu W, Wang LH, Li ZN, Xu Y, et al: Twist induces epithelial-mesenchymal transition in cervical carcinogenesis by regulating the TGF-β/Smad3 signaling pathway. Oncol Rep. 34:1787–1794. 2015.PubMed/NCBI View Article : Google Scholar
19	Bao W, Qiu H, Yang T, Luo X, Zhang H and Wan X: Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 8(e70616)2013.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 8:384–393. 2015.PubMed/NCBI
22	Zheng L, Kang Y, Zhang L and Zou W: MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR. Cancer Biol Ther. 21:34–42. 2020.PubMed/NCBI View Article : Google Scholar
23	Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, et al: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 3(e4029)2008.PubMed/NCBI View Article : Google Scholar
24	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
25	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012.PubMed/NCBI View Article : Google Scholar
26	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar
27	Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L and Nuchnoi P: Cervical cancer markers: Epigenetics and microRNAs. Lab Med. 49:97–111. 2018.PubMed/NCBI View Article : Google Scholar
28	Luhn P, Walker J, Schiffman M, Zuna RE, Dunn ST, Gold MA, Smith K, Mathews C, Allen RA, Zhang R, et al: The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol. 128:265–270. 2013.PubMed/NCBI View Article : Google Scholar
29	Chung SH, Wiedmeyer K, Shai A, Korach KS and Lambert PF: Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 68:9928–9934. 2008.PubMed/NCBI View Article : Google Scholar
30	Chung SH, Franceschi S and Lambert PF: Estrogen and ERalpha: Culprits in cervical cancer? Trends Endocrinol Metab. 21:504–511. 2010.PubMed/NCBI View Article : Google Scholar
31	Lopez-Romero R, Garrido-Guerrero E, Rangel-Lopez A, Manuel-Apolinar L, Piña-Sánchez P, Lazos-Ochoa M, Mantilla-Morales A, Bandala C and Salcedo M: The cervical malignant cells display a down regulation of ER-α but retain the ER-β expression. Int J Clin Exp Pathol. 6:1594–1602. 2013.PubMed/NCBI
32	Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER and Cho KR: Loss of estrogen receptor 1 enhances cervical cancer invasion. The American journal of pathology. 177:884–895. 2010.PubMed/NCBI View Article : Google Scholar
33	Deligeoroglou E, Michailidis E and Creatsas G: Oral contraceptives and reproductive system cancer. Annals of the New York Academy of Sciences. 997:199–208. 2003.PubMed/NCBI View Article : Google Scholar
34	Miller N, Bedard YC, Cooter NB and Shaul DL: Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology. 10:661–669. 1986.PubMed/NCBI View Article : Google Scholar
35	Jiang H, Yu WW, Wang LL and Peng Y: miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncology reports. 34:1153–1161. 2015.PubMed/NCBI View Article : Google Scholar
36	Liu SG, Qin XG, Zhao BS, et al: Differential expression of miRNAs in esophageal cancer tissue. Oncology letters. 5:1639–1642. 2013.PubMed/NCBI View Article : Google Scholar
37	Chi C, Mao M, Shen Z, Chen Y, Chen J and Hou W: HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells. Human gene therapy. 29:1438–1448. 2018.PubMed/NCBI View Article : Google Scholar
38	Hofsjo A, Bohm-Starke N, Bergmark K, Masironi B and Sahlin L: Sex steroid hormone receptor expression in the vaginal wall in cervical cancer survivors after radiotherapy. Acta oncologica. 58:1107–1115. 2019.PubMed/NCBI View Article : Google Scholar
39	Zhang HD, Jiang LH, Sun DW, Li J and Ji ZL: The role of miR-130a in cancer. Breast cancer. 24:521–527. 2017.PubMed/NCBI View Article : Google Scholar
40	Yin S, Zhang Q, Wang Y, Li S and Hu R: MicroRNA-130a regulated by HPV18 E6 promotes proliferation and invasion of cervical cancer cells by targeting TIMP2. Experimental and therapeutic medicine. 17:2837–2846. 2019.PubMed/NCBI View Article : Google Scholar